About 100 guests from 36 countries met on the XVIII. MetaSystems Distributor Meeting (DM) in November to exchange experiences and to get to know new trends and developments at MetaSystems.

Our internet site may contain information that is not approved in all countries or regions. To ensure accuracy of content, please select your country/region of residence. Choose International if your country is not listed.
This information will be saved using cookies. To find out more about cookies, read our Privacy Policy.
Please select your country of residence. Choose International if your country is not listed.
Our internet site may contain information that is not approved in all countries or regions. To ensure accuracy of content, it is required that you select the site which is appropriate for your country of residence.
XL ETV6 consists of an orange-labeled probe hybridizing proximal to the ETV6 gene region at 12p13.2 and a green-labeled probe hybridizing distal to the ETV6 gene region at 12p13.2.
Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.
The ETV6 gene, located on 12p13.2, is involved in numerous translocations found in myeloid and lymphoid malignancies. Two mechanisms are common: fusion to a tyrosine kinase resulting in a constitutively active tyrosine kinase and fusions to transcription factors driving aberrant expression of target genes. The frequent translocation t(12;21)(p13;q22) results in the formation of the chimeric transcription factor ETV6-RUNX1 which can be identified in about 25% of childhood B-cell acute lymphoblastic leukemia (B-ALL) cases. ETV6-RUNX1 causes expansion of B-cell precursors with impaired ability of differentiation to mature B-cells. Another important aberration is t(5;12)(q33;p13), found in chronic myelomonocytic leukemia (CML) and myeloproliferative diseases, resulting in the fusion of ETV6 with the receptor tyrosine kinase PDGFRB. The resulting oncogene is sensitive to the kinase inhibitor imatinib. t(7;12)(q36;p13) can be identified in pediatric acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is resulting in the fusion gene MNX1-ETV6.
Besides hematological malignancies, ETV6 is also involved in the development of the pediatric congenital mesoblastic nephroma and fibrosarcoma. t(12;15)(p13;q25) fuses ETV6 to the tyrosin receptor kinase NTRK3 resulting in the ETV6-NTRK3 fusion gene, a constitutively active tyrosine kinase.
Normal Cell:
Two green-orange (2GO) fusion signals representing the two normal ETV6 loci.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and one green-orange (1GO) fusion signal, indicating a chromosome break in the ETV6 locus.
Certificate of Analysis (CoA)
or go to CoA Database